Personal information

Other IDs

Scopus Author ID: 48761172400
ResearcherID: AAY-1505-2020

Activities

Collapse all

Employment (2)

IRCCS Humanitas Research Hospital: Rozzano, Lombardia, IT

2021-03-01 to present
Employment
Source: Self-asserted source
Ilaria Fuso Nerini

Istituto di Ricerche Farmacologiche Mario Negri: Milano, Lombardia, IT

2009-04-15 to 2021-02-28
Employment
Source: Self-asserted source
Ilaria Fuso Nerini

Works (19)

Genomic instability analysis in DNA from Papanicolaou test provides proof-of-principle early diagnosis of high-grade serous ovarian cancer

Science Translational Medicine
2023-12-06 | Journal article | Author
DOI: 10.1126/scitranslmed.adi2556
Part of ISSN: 1946-6234
Part of ISSN: 1946-6242
Contributors: Lara Paracchini; Laura Mannarino; Chiara Romualdi; Riccardo Zadro; Luca Beltrame; Ilaria Fuso Nerini; Paolo Zola; Maria Elena Laudani; Eva Pagano; Livia Giordano et al.
Source: Self-asserted source
Ilaria Fuso Nerini

Quantitative measurement of pioglitazone in neoplastic and normal tissues by AP-MALDI mass spectrometry imaging

Talanta
2022-01 | Journal article
DOI: 10.1016/j.talanta.2021.122918
Part of ISSN: 0039-9140
Source: Self-asserted source
Ilaria Fuso Nerini

PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models

Journal of Experimental & Clinical Cancer Research
2021-12 | Journal article
DOI: 10.1186/s13046-021-02070-x
Part of ISSN: 1756-9966
Source: Self-asserted source
Ilaria Fuso Nerini

VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status

Journal of Hematology & Oncology
2021-12 | Journal article
DOI: 10.1186/s13045-021-01196-x
Part of ISSN: 1756-8722
Source: Self-asserted source
Ilaria Fuso Nerini

Is DNA repair a potential target for effective therapies against malignant mesothelioma?

Cancer Treatment Reviews
2020-11 | Journal article
DOI: 10.1016/j.ctrv.2020.102101
Part of ISSN: 0305-7372
Source: Self-asserted source
Ilaria Fuso Nerini

Preclinical models in mesothelioma

Mesothelioma
2019-07 | Book chapter
Source: Self-asserted source
Ilaria Fuso Nerini

Drug development (Including phase I trials)

ESMO Handbook of Interpreting Oncological Study Publications
2018 | Book chapter
Source: Self-asserted source
Ilaria Fuso Nerini

Not only tumor but also therapy heterogeneity

Annals of Oncology
2018 | Journal article
DOI: 10.1093/annonc/mdx646
EID:

2-s2.0-85041205180

Part of ISBN:

15698041 09237534
Contributors: Garattini, S.; Fuso Nerini, I.; D'Incalci, M.
Source: Self-asserted source
Ilaria Fuso Nerini via Scopus - Elsevier

Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations

Cancer Chemotherapy and Pharmacology
2017 | Journal article
DOI: 10.1007/s00280-017-3307-8
EID:

2-s2.0-85018483198

Part of ISBN:

14320843 03445704
Contributors: Ballerini, A.; Moro, F.; Nerini, I.F.; Marzo, C.M.; Di Clemente, A.; Ferrari, M.; D’Incalci, M.; Biondi, A.; Colombini, A.; Conter, V. et al.
Source: Self-asserted source
Ilaria Fuso Nerini via Scopus - Elsevier

Bevacizumab-induced inhibition of angiogenesis promotes a more homogeneous intratumoral distribution of paclitaxel, improving the antitumor response

Molecular Cancer Therapeutics
2016 | Journal article
DOI: 10.1158/1535-7163.MCT-15-0063
EID:

2-s2.0-84958157844

Part of ISBN:

15388514 15357163
Contributors: Cesca, M.; Morosi, L.; Berndt, A.; Nerini, I.F.; Frapolli, R.; Richter, P.; Decio, A.; Dirsch, O.; Micotti, E.; Giordano, S. et al.
Source: Self-asserted source
Ilaria Fuso Nerini via Scopus - Elsevier

Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging

Scientific Reports
2016 | Journal article
DOI: 10.1038/srep39284
EID:

2-s2.0-85006986919

Part of ISBN:

20452322
Contributors: Giordano, S.; Zucchetti, M.; Decio, A.; Cesca, M.; Fuso Nerini, I.; Maiezza, M.; Ferrari, M.; Licandro, S.A.; Frapolli, R.; Giavazzi, R. et al.
Source: Self-asserted source
Ilaria Fuso Nerini via Scopus - Elsevier

Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics.

Chinese journal of cancer
2016-06-29 | Journal article
DOI: 10.1186/s40880-016-0123-1
PMID: 27357621
PMC: PMC4928348
Source: Self-asserted source
Ilaria Fuso Nerini

Intratumor heterogeneity and its impact on drug distribution and sensitivity

Clinical Pharmacology and Therapeutics
2014 | Journal article
DOI: 10.1038/clpt.2014.105
EID:

2-s2.0-84904856656

Part of ISBN:

15326535 00099236
Contributors: Fuso Nerini, I.; Morosi, L.; Zucchetti, M.; Ballerini, A.; Giavazzi, R.; D'incalci, M.
Source: Self-asserted source
Ilaria Fuso Nerini via Scopus - Elsevier

MiRNA landscape in stage i epithelial ovarian cancer defines the histotype specificities

Clinical Cancer Research
2013 | Journal article
DOI: 10.1158/1078-0432.CCR-13-0360
EID:

2-s2.0-84881258346

Part of ISBN:

15573265 10780432
Contributors: Calura, E.; Fruscio, R.; Paracchini, L.; Bignotti, E.; Ravaggi, A.; Martini, P.; Sales, G.; Beltrame, L.; Clivio, L.; Ceppi, L. et al.
Source: Self-asserted source
Ilaria Fuso Nerini via Scopus - Elsevier

Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer

European Journal of Cancer
2013 | Journal article
DOI: 10.1016/j.ejca.2012.06.026
EID:

2-s2.0-84872114095

Part of ISBN:

09598049 18790852
Contributors: Marchini, S.; Fruscio, R.; Clivio, L.; Beltrame, L.; Porcu, L.; Nerini, I.F.; Cavalieri, D.; Chiorino, G.; Cattoretti, G.; Mangioni, C. et al.
Source: Self-asserted source
Ilaria Fuso Nerini via Scopus - Elsevier

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

Cancer Cell
2013 | Journal article
DOI: 10.1016/j.ccr.2013.01.008
EID:

2-s2.0-84873597334

Part of ISBN:

15356108 18783686
Contributors: Germano, G.; Frapolli, R.; Belgiovine, C.; Anselmo, A.; Pesce, S.; Liguori, M.; Erba, E.; Uboldi, S.; Zucchetti, M.; Pasqualini, F. et al.
Source: Self-asserted source
Ilaria Fuso Nerini via Scopus - Elsevier

A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma

PLoS ONE
2012 | Journal article
DOI: 10.1371/journal.pone.0035423
EID:

2-s2.0-84859856689

Part of ISBN:

19326203
Contributors: Uboldi, S.; Calura, E.; Beltrame, L.; Nerini, I.; Marchini, S.; Cavalieri, D.; Erba, E.; Chiorino, G.; Ostano, P.; D'Angelo, D. et al.
Source: Self-asserted source
Ilaria Fuso Nerini via Scopus - Elsevier

Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents

International Journal of Cancer
2012 | Journal article
DOI: 10.1002/ijc.26340
EID:

2-s2.0-84860220336

Part of ISBN:

00207136 10970215
Contributors: Uboldi, S.; Bernasconi, S.; Romano, M.; Marchini, S.; Fuso Nerini, I.; Damia, G.; Ganzinelli, M.; Marangon, E.; Sala, F.; Clivio, L. et al.
Source: Self-asserted source
Ilaria Fuso Nerini via Scopus - Elsevier

Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: A retrospective study of two independent tumour tissue collections

The Lancet Oncology
2011 | Journal article
DOI: 10.1016/S1470-2045(11)70012-2
EID:

2-s2.0-79952041791

Part of ISBN:

14702045
Contributors: Marchini, S.; Cavalieri, D.; Fruscio, R.; Calura, E.; Garavaglia, D.; Nerini, I.F.; Mangioni, C.; Cattoretti, G.; Clivio, L.; Beltrame, L. et al.
Source: Self-asserted source
Ilaria Fuso Nerini via Scopus - Elsevier
How many people are using ORCID?